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Alcohol and drugs in seriously injured drivers
in six European countries
Sara-Ann Legrand,a* Cristina Isalberti,a Trudy Van der Linden,b
Inger Marie Bernhoft,c Tove Hels,c Kirsten Wiese Simonsen,d
Donata Favretto,e Santo Davide Ferrara,e Marija Caplinskiene,f
Zita Minkuviene,f Alvydas Pauliukevicius,f Sjoerd Houwing,g
René Mathijssen,g Pirjo Lillsunde,h Kaarina Langel,h Tom Blencoweh and
Alain G. Verstraetea
The objective of this study was to determine the presence of alcohol and drugs in drivers severely injured in trafﬁc crashes in
six European countries. Data were collected from 2492 seriously injured drivers of cars and vans in Belgium, Denmark, Finland,
Italy, Lithuania, and the Netherlands, between 2007 and 2010. Toxicological analysis was performed with chromatographic
techniques on whole blood for 23 substances. The percentage of drivers positive for at least one psychoactive substance
ranged between 28% (Lithuania) and 53% (Belgium). Alcohol (≥0.1 g/L) was the most common ﬁnding with the highest
percentage in Belgium (42.5%). Among the alcohol-positive drivers, 90.5% had a blood alcohol count (BAC) ≥0.5 g/L and
65.7% had a BAC ≥1.3 g/L. Benzodiazepines (0.0–10.2%) and medicinal opioids (0.5–7.8%) were the most prevailing medicinal
drugs, but half of the concentrations were lower than therapeutic. Cannabis (0.5–7.6%) was the most prevailing illicit drug.
Alcohol was found in combination with drugs in 2.3-13.2% of the drivers. Drug combinations were found in 0.5–4.3% of the
drivers. This study conﬁrms the high prevalence of psychoactive substances in injured drivers, but we observed large differ-
ences between the participating countries. Alcohol was the most common ﬁnding, followed by cannabis and benzodiazepines.
Notable are the many drivers having a BAC ≥1.3 g/L. The majority of the substances were found in combination with another
psychoactive substance, mostly alcohol. The high prevalence of high BACs and combinations (compared to roadside surveys)
suggest that those drivers are most at risk and that preventive actions should target them preferentially. Copyright © 2012
John Wiley & Sons, Ltd.
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Introduction
Driving under the inﬂuence of drugs other than alcohol is a signif-
icant problem all over the world.[1] Both illicit and licit drugs that
affect the central nervous system have a high potential to increase
crash risk.[2–8] The prevalence of alcohol and drugs among injured
drivers is well documented in the literature.[4–6,8–18] However,
epidemiological studies are difﬁcult to compare with each other
because of differences in study design. For example, the sampled
population can differ in socio-demographical factors such as age
and gender.[19] Some studies only included drivers of a car[3,20]
while other studies included drivers of different types of vehicles
(e.g. motorcycles and bicycles).[21,22] Some studies were performed
24/7 while other were conducted only during the weekend.[23]
Different types of biological samples have been used (urine, blood,
saliva). The use of urine samples may lead to an overestimation of
the prevalence of psychoactive substances since drugs (and meta-
bolites) can be detected for a relatively long period after consump-
tion. All these factors inﬂuence the outcome of these studies and
consequently make it difﬁcult to compare the results.
The objective of the present study was to assess the presence of
alcohol and other psychoactive substances in drivers of cars and
vans who have been injured in trafﬁc crashes in various European
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countries by means of analysis of blood samples of injured drivers.
Including several European countries allowed for the assessment of
differences in prevalence of psychoactive substances between
the countries.
A uniform study design[24] minimized the problem of compara-
bility of data, which is also a problem underlined by, for example,
the European Monitoring Center for Drugs and Drug Addiction
(EMCDDA) and the Working Group on Illegal Drugs & Driving
(ICADTS).[25–27] This uniformed study design and an extensive data
collection of nearly 2500 seriously injured drivers distinguish the
present epidemiological study from previous studies. This study
was performed in the framework of the EU research project Driving
under the Inﬂuence of Drugs, Alcohol and Medicines (DRUID).
Materials and methods
Study setting and population
The study was conducted in different European countries
between October 2007 and April 2010. We tried to include
countries from all parts of Europe. Because of difﬁculties in orga-
nizing previous similar studies, some countries decided not to
participate. Sweden and Hungary had to withdraw due to difﬁcul-
ties in collecting enough samples. Eventually six countries were
included: Belgium (BE), Denmark (DK), Finland (FI), Italy (IT),
Lithuania (LT), and the Netherlands (NL). The study population
consisted of 2492 samples (BE: 348; DK: 840; FI: 54; IT: 676;
LT:387; NL:187).
The study population was selected by multistage clustering
sampling. First a selection of hospitals was made in each country
based on willingness to cooperate, geographical distribution, and
inﬂux of injured drivers. There were ﬁve hospitals in each country
(Belgium and Denmark), one in Finland, four in Italy and Lithuania,
and three in the Netherlands. The study population consisted of
seriously injured drivers who were admitted to the emergency
department (ED) of a hospital in the six countries involved. Only
drivers of cars and vans were included. The interval between crash
and sampling had to be less than 3h. Cases with a longer interval
were not included because the drug concentrations are less repre-
sentative of those at the time of the crash. Only drivers aged 18 and
above and with a Maximum Abbreviated Injury Scale (MAIS) ≥2
were included.[28,29] The MAIS scale runs from 1–6, with a score of
1 indicating minor injury and 6 indicating death; with four
in-betweenstages: moderate, severe, serious and critical injury.[28]
The MAIS score was not available in Denmark and Italy, but other
national criteria were used to guarantee inclusion of patients with
an injury severity equivalent to MAIS score 2 or higher.
Data sources
Two sources of data were used. Standardized patient informa-
tion (age, gender, time and date of sampling, medication/
ﬂuids administered prior to blood sampling, and MAIS score)
and crash data (time and date, type of vehicle, type of
crash (single/multivehicle), road type and seat-belt use) were
gathered through means of a questionnaire that was ﬁlled
in by the hospital staff. Information about the use of a seat
belt was only collected in Belgium and the Netherlands.
Furthermore, a blood sample was collected. Eight substance
groups were chosen for analysis based on their prevalence
of use and the likelihood of them playing a role in road
crashes: alcohol, amphetamines, cocaine, cannabinoids (THC),
benzodiazepines, illicit and medicinal opioids, and Z-drugs
(zolpidemand zolpiclone).
Toxicological analyses
The toxicological analyses were performed on whole blood. Five
to ten ml of whole blood was collected in grey-top vacuum tubes
containing sodium ﬂuoride and potassium oxalate. The conditions
of sample transportation and storage as well as the analytical
methods have been described in detail elsewhere.[24,30,31] The
target substances as well as the analytical cut-off values are listed
in Table 1, which also shows the mean and median concentrations.
The samples from all countries have been pooled. For analysis of
the toxicological ﬁndings, drugs were grouped according to
their pharmacological characteristics. Samples positive for
medicinal drugs administered before the blood sample was taken
were considered negative for these substances. Substances of
the same type were combined in substance groups. A case
was positive for cannabinoids when THC was found. Thus a case
where only the inactive metabolite THCCOOH was detected, was
considered negative. A driver was considered positive for cocaine
when cocaine alone or in combination with benzoylecgonine
was measured.
Statistical analyses
Chi-square analysis was used to search for differences between
countries. SPSS statistics 17 (IBM, Somers NY, USA) was used for
statistical analysis. The level of signiﬁcance was set at p< 0.05.
Conﬁdence intervals were calculated with the Wilson method.[32]
Multiple regression was used to correct for age and gender. The
Kruskall Wallis one-way ANOVA test was used to make pairwise
comparisons between groups of drivers. The Bonferroni correc-
tion was applied to calculate adjusted signiﬁcance values.
Ethical approval
To guarantee conﬁdentiality no references were made in the
medical record about the inclusion of a patient in the study. All
forms and samples were given a unique and anonymous code.
The study protocol complied with recognized standards of
human subjects protection. Ethical approval was obtained in
Belgium, Finland, Lithuania, and the Netherlands. No ethical
approval was needed in Denmark and Italy. In three out of the
six countries, an informed consent form had to be signed by
the respondent or relative (BE, FI, IT).
Results
Description of the studied population
A description of the studied population can be found in Table 2.
Signiﬁcant differences between countries were found (p< 0.01)
for age and gender, crash type, distribution by time of the week
and time of the day and injury severity. There were relatively more
male drivers injured in the Netherlands and Italy than in the other
countries. The age group 18–24 was less present in Belgium and
Italy. For the age group 25–34 a higher proportion was seen in Italy.
There weremore weekday trafﬁc crashes in Denmark and Lithuania
compared to the other four countries. A signiﬁcant difference in
MAIS scores (2 and 3) was found (p< 0.01) between Belgium and
the Netherlands, with more MAIS 2 cases in Belgium.
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The non-response rate ranged from 0% (IT and LT) up to 8.5% (FI)
(Table 2). Reasons for not participating were: not willing to give
an extra blood sample, severe injuries or time pressure. Moreover,
subjects not fulﬁlling the above mentioned inclusion criteria (e.g.
because they were not driving a car) were excluded (in BE: 730;
DK: 16; FI: 271; IT: 14; LT:37; NL:10).
Prevalence of alcohol and drugs in injured drivers
Prevalence of drug and alcohol-positive drivers
The highest percentage of drivers positive for one or more sub-
stances was found in Belgium (52.6%), which was signiﬁcantly
higher than in Denmark, Italy, Lithuania, and the Netherlands
(p< .05) (Table 3). In these four countries, the percentage of
alcohol or drug-positive drivers was approximately 30%. Male
drivers were more often positive for alcohol and drugs than
female drivers with the highest percentage found in Belgium
(59.1%). In all six countries, the prevalence of drugs and alcohol
was higher in drivers younger than 35 years.
Alcohol
The percentage of drivers positive for alcohol alone (BAC≥ 0.1 g/L)
ranged between 14.4% and 29.9% and for alcohol in combination
with other substances between 2.3 and 13.2% (Table 3). In Belgium,
signiﬁcantly more injured drivers tested positive for alcohol com-
pared to Denmark, Italy, Lithuania, and the Netherlands (p< .05).
Even after correction for age and gender, the signiﬁcant difference
between Belgium and the four other countries persisted. The
percentage of drivers testing positive for alcohol (BAC≥ 0.5 g/L) –
the legal limit in most countries involved – ranged between
approximately 16 and 38%. Of the 609 drivers found positive for
alcohol, 9.5% (5.5% (NL)–10.9% (IT)) had a BAC between 0.1g/L
and 0.5 g/L and 65.7% (58.2% (NL)–76.5% (FI)) had a BAC≥ 1.3g/L
(Figure 1). The median alcohol concentration was 1.6 g/L. No signif-
icant differences in alcohol concentrations were found between
the countries.
In Belgium, Denmark, Italy, and the Netherlands, signiﬁcantly
more male drivers tested positive for alcohol compared to female
drivers (p< .05). In all six countries, alcohol-positives peaked in
drivers younger than 35 years, with signiﬁcant differences
between the age groups in DK, IT and NL (p< .05).
Illicit drugs
The prevalence of amphetamines ranged between 0.1 (IT) and
4.2% (DK) (Table 3). Even after correction for age and gender,
Italian drivers tested signiﬁcantly less positive for amphetamine
compared to the other ﬁve countries (p< .05). Roughly more
male than female drivers tested positive for amphetamines, but
this was signiﬁcant only in Denmark (p< .05). Amphetamines
were mostly observed in combination with benzodiazepines
and alcohol.
The highest prevalence of cocaine was recorded in Italy (2.7%,
CI: 1.7–4.2), which was signiﬁcantly more than in Lithuania and
Denmark (p< .05). A higher prevalence, yet not signiﬁcant, of
cocaine was found in male drivers, except for the Netherlands
Table 1. Distribution of concentrations. All concentrations in mg/L except for ethanol: g/L
Substance Substance
groups
DRUID
cut-off
(ng/ml)
Number of
samples
screened
Concentrations at or above DRUID cut-off
n Positive Mean Median
Ethanol Alcohol 0.1 g/L 2486 609 1.59 g/L 1.60 g/L
6-acetylmorphine Illicit opioids* 10 2484 1 12.4 12.4
Amphetamine Amphetamines 20 2485 45 215 102
Methamphetamine 20 2485 11 112 125
MDA 20 2485 1 43.1 43.4
MDEA 20 2485 0 N.A. N.A.
MDMA 20 2485 5 199 93.9
Alprazolam Benzodiazepines 10 2484 6 52.3 44.5
Clonazepam 10 2484 30 45.8 40.2
Diazepam 20 2480 41 234 112
Lorazepam 10 2483 13 37.7 25.6
Flunitrazepam 2 2480 4 8.5 8.0
Nordiazepam 20 2481 46 223 138
Oxazepam 50 2483 14 303 174
Cocaine Cocaine** 10 2484 36 59.5 35.5
Codeine Medicinal opioids 10 2484 18 27.1 20.5
Methadone 10 2483 29 140 72.0
Morphine 10 2470 58 65.3 31.5
THC Cannabis*** 1 2481 68 3.0 2.3
Zolpidem Z-drugs 20 2484 11 238 131
Zopiclone 10 2484 8 103 59.6
* Illicit opioids: 6-acetylmorphine or (morphine+ codeine and morphine concentration≥ codeine concentration). Concentrations of 6-acetylmorphine
and/or codeine, when present, were taken into consideration even when below the DRUID cut-off.
** Cocaine: Cocaine+ Benzoylecgonine or cocaine.
*** Cannabis: THC or THC+ THCCOOH.
N.A.: Not applicable.
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were we did ﬁnd a signiﬁcant difference (p< .05). Cocaine was
more often found combined than alone.
Belgium and Finland had a signiﬁcantly higher prevalence of
cannabis than the other four countries (p< .05) (Table 3). This
signiﬁcance disappears for Finland when correcting for age
and gender. In all countries, male drivers tested more
frequently positive for THC than female drivers (only signiﬁcant
in Belgium, p< .05). No female drivers tested positive for THC in
Finland, Lithuania, and the Netherlands. In general, THC was
more prevalent among drivers younger than 35 years. THC was
often found combined with other substances, mostly alcohol.
Italian drivers (2.1%, CI: 1.6–3.5) tested signiﬁcantly more
frequently positive for illicit opiates than Danish, Lithuanian,
and Dutch drivers (p< .05). Apart from one case in Italy, all
Table 2. Description of the injured driver sample in six European countries
Countries BE
% (N)
DK
% (N)
FI
% (N)
IT
% (N)
LT
% (N)
NL
% (N)
Total
Total N (%) 14.0 (348) 33.7 (840) 2.2 (54) 27.1 (676) 15.5 (387) 7.5 (187) 2492
Week and time of the day (%, N between brackets)*
N 339 822 54 638 361 187
Weekdaya 43.1 (146) 61.2 (503) 44.4 (24) 41.4 (264) 66.8 (241) 48.1 (90) 52.8 (1268)
Weekend dayb 28.3 (96) 25.8 (212) 35.2 (19) 33.5 (214) 23.5 (85) 12.3 (23) 27.0 (649)
Week nightc 13.3 (45) 4.7 (39) 9.3 (5) 11.1 (71) 3.0 (11) 24.6 (46) 9.0 (217)
Weekend nightd 15.3 (52) 8.3 (68) 11.1 (6) 13.9 (89) 6.6 (24) 15.0 (28) 11.1 (267)
Gender (%)*
N 347 840 54 676 374 187 2478
Male 70.0 (243) 65.1 (547) 79.6 (43) 76.9 (520) 63.9 (239) 80.2 (150) 70.3 (1742)
Female 30.0 (104) 34.9 (293) 20.4 (11) 23.1 (156) 36.1 (135) 19.8 (37) 29.7 (736)
Age groups (%)*
N 335 834 54 676 363 187 2449
18–24y 21.2 (71) 32.3 (269) 31.5 (17) 18.6 (126) 28.9 (105) 29.4 (55) 26.3 (643)
25–34y 31.6 (106) 24.5 (204) 20.4 (11) 30.8 (208) 26.4 (96) 27.2 (51) 27.6 (676)
35–49y 26.3 (88) 25.8 (215) 18.5 (10) 30.2 (204) 28.9 (104) 24.5 (46) 27.2 (667)
50+ 21.0 (70) 17.5 (146) 29.6 (16) 20.4 (138) 16.0 (58) 18.7 (35) 18.9 (463)
Safety belt use (%)
N 301 N.A. N.A. N.A. N.A. 143 444
Yes 71.4 (215) 74.1 (106) 72.3 (321)
No 28.6 (86) 25.9 (37) 27.7 (123)
Vehicle type (%)
N 348 831 54 615 373 187 2408
Personal car 93.1 (324) 94.9 (789) 94.4 (51) 93.8 (577) 92.8 (346) 94.1 (176) 94.0 (2263)
Van 6.9 (24) 5.1 (42) 5.6 (3) 6.2 (38) 7.2 (27) 5.9 (11) 6.0 (145)
Crash type (%)*
N 323 826 51 na 373 161 1734
Single vehicle 48.9 (158) 49.8 (411) 49.0 (25) 29.5 (110) 62.7 (101) 46.4 (805)
Multi vehicles 51.1 (165) 50.2 (415) 51.0 (26) 70.5 (263) 32.1 (60) 53.6 (929)
Injury severity (%)*
N 337 840 53 676 154 186 2246
2 61.7 (208) 0 56.6 (30) 0 88.3 (136) 48.9 (91) 20.7 (465)
3 28.8 (97) 0 39.6 (21) 0 7.8 (12) 35.5 (66) 8.7 (196)
4 5.9 (20) 0 3.8 (2) 0 2.6 (4) 8.6 (16) 1.9 (42)
5 3.6 (12) 0 0 0 0.6 (1) 7.0 (13) 1.2 (26)
6 0 0 0 0 0.6 (1) 0 0.04 (1)
Equivalent** 0 100 0 100 0 0 67.5
Non response rate (%) 5.4 Unknown*** 8.5 0 0 Unknown***
N=Number of drivers for which the information was recorded.
* Signiﬁcant difference.
** A different scoring system was used in Denmark and Italy.
*** No registration of or information on the patients that refused is available.
N.A. = not applicable (not recorded).
aMonday–Thursday 4.00–22.00.
bFriday–Sunday 4.00–22.00.
cMonday–Thursday 22.00–4.00.
dFriday–Sunday 22.00–4.00.
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Table 3. Prevalence in percentage (N between brackets) of alcohol and drugs in seriously injured drivers in 6 European countries
BELGIUM DENMARK FINLAND ITALY LITHUANIA THE NETHERLANDS
% (N) % (N) %(N) % (N) % (N) % (N)
Positive driversa 52.6 (171) 30.3 (252) 44.7 (21) 32.0 (216) 27.8 (107) 33.9 (63)
CI 47.3–57.8 27.3–33.5 32.2–57.9 28.6–35.6 23.6–32.5 27.5–40.9
Female 37.2 (35) 15.8 (46) 20.0 (2) 23.7 (37) 20.9 (28) 13.5 (5)
Male 59.1 (136) 38.1 (206) 51.4 (19) 34.4 (179) 32.4 (77) 38.9 (58)
<35y 55.4 (92) 31.6 (148) 53.8 (14) 38.0 (127) 28.1 (56) 39.6 (42)
≥35y 47.9 (70)g 28.3(101)d 28.3 (7) 26.0 (89) 27.8 (45)f 26.3 (21)
Alcohol
≥0.1 g/L 42.5 (148) 19.7 (165) 32.1 (17) 23.1 (156) 17.7 (68) 29.6 (55)
CI 37.4–47.8 17.2–22.5 21.2–45.4 20.0–26.4 14.2–21.8 23.5–36.5
Alone 29.9 (98) 14.4 (117) 22.6 (12) 18.5 (125) 15.2 (59) 25.3 (47)
Male 50.6(123)* 27.3 (149)* 35.7 (15) 25.0 (130)* 19.3 (46) 34.2 (51)*
Female 24.0 (25) 5.5 (16) 18.2 (2) 16.7 (26) 16.4 (22) 10.8 (4)
<35y 45.8 (81) 22.5 (106)* 42.9 (12) 26.3 (88)* 19.6 (39) 35.8 (38)*
≥35y 38.0 (60) 16.1 (58) 20.0 (5) 19.9 (68) 16.0 (26)e 21.3 (17)
0.1 g/L ≤ alcohol≤
0.5 g/L CI
4.3 (15) 2.6–7.0 1.9 (16) 1.2–3.1 1.9 (1) 0.3–9.8 2.5 (17) 1.6–4.0 1.6 (6) 0.7–3.4 1.6 (3) 0.5–4.6
≥0.5 g/L CI 38.2 (133) 33.3–43.4 17.8 (149) 15.3–20.5 30.2 (16) 19.6–43.4 20.6 (139) 17.7–23.8 16.1 (62) 12.7–20.1 28.0 (52) 22.1–34.8
Amphetamines 2.6 (9) 4.2 (35) 3.7 (2) 0.1 (1) 0.6 (2) 2.2 (4)
CI 1.4–4.9 3.0–5.8 1.0–12.5 0.0–0.8 0.2–2.0 0.9–5.5
Alone 0.9 1.0 0.0 0.0 0.3 1.1
Male 3.3 (8) 5.3 (29)* 4.7 (2) 0.1 (1) 0.8 (2) 2.0 (3)
Female 1.0 (1) 2.0 (6) 0.0 (0) 0.0 (0) 0.0 (0) 2.7 (1)
<35y 3.4 (6) 6.3 (30)* 3.6 (1) 0.0 (0) 0.0 (0) 3.8 (4)
≥35y 1.9 (3) 1.4 (5) 3.8 (1) 0.3 (1) 1.2 (2) 0.0 (0)
Cocaine 2.3 (8) 0.6 (5) 0.0 2.7 (18) 0.3 (1) 2.1 (4)
CI 1.2–4.5 0.3–1.4 0.0–6.6 1.7–4.2 0.1–1.5 0.8–5.3
Alone 0.0 0.0 0.6 0.3 0.0
Male 3.3 (8) 0.9 (5) 3.3 (17) 0.4 (1) 2.0 (3)
Female 0.0 (0) 0.0 (0) 0.6 (1) 0.0 (0) 2.7 (1)
<35y 3.4 (6) 1.1 (5)* 2.4 (8) 0.0 (0) 3.8 (4)
≥35y 0.6 (1)b 0.0 (0) 2.9 (10) 0.6 (1) 0.0 (0)
THC 7.6 (26) 1.3 (11) 5.7 (3) 3.7 (25) 0.5 (2) 0.5 (1)
CI 5.3–10.9 0.7–2.3 2.0–15.3 2.5–5.4 0.1–1.8 0.1–2.9
Alone 1.5 0.6 1.9 1.6 0.3 0.5
Male 10.0 (24)* 1.8 (10) 7.1 (3) 4.4 (23) 0.8 (2) 0.7 (1)
Female 2.0 (2) 0.3 (1) 0.0 (0) 1.3 (2) 0.0 (0) 0.0 (0)
<35y 13.6 (24)* 1.3 (6) 10.7 (3) 6.0 (20)* 0.5 (1) 0.9 (1)
≥35y 0.6 (1)b 1.4 (5) 0.0 (0) 1.5 (5) 0.6 (1) 0.0 (0)
Illicit opiates 0.6 (2) 0.5 (4) 0.0 2.1 (14) 0.3 (1) 0.0
CI 0.2–2.1 0.2–1.3 0.0–6.6 1.6–3.5 0.1–1.5 0.0–2.0
Alone 0.0 0.0 0.7 0.0
Male 0.8 (2) 0.7 (4) 2.5 (13) 0.4 (1)
Female 0.0 (0) 0.0 (0) 0.6 (1) 0.0 (0)
<35y 0.6 (1) 0.0 (0) 2.7 (9) 0.5 (1)
≥35y 0.6 (1) 1.1 (4)* 1.5 (5) 0.0 (0)
Benzodiazepines 7.3 (25) 6.7 (56) 10.2 (5) 0.7 (5) 3.6 (14) 0.0
CI 5.0–10.5 5.2–8.6 4.6–21.1 0.3–1.7 2.1–6.0 0.0–2.0
Alone 1.5 1.2 0.0 0.4 2.3
Male 6.7 (16) 7.6 (41) 12.8(5) 0.2 (1) 4.2 (10)
Female 8.9 (9) 5.1 (15) 0.0 (0) 2.6 (4)* 3.0 (4)
<35y 1.7 (3) 6.8 (32) 11.1 (3) 0.3 (1) 3.0 (6)
≥35y 11.5 (18)*c 6.4 (23) 9.1 (2) 1.2 (4) 4.3 (7)b
Z–drugs 1.8 (6) 1.2 (10) 3.8 (2) 0.0 0.0 0.5 (1)
CI 0.8–3.8 0.7–2.2 1.2–12.7 0.0–0.6 0.0–1.0 0.1–2.9
Alone 0.9 0.5 1.9 0.5
Male 0.4 (1) 1.1 (6) 4.8 (2) 0.7 (1)
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drivers positive for illicit opiates were male. Out of 21 cases from
all countries, 16 were in combination with other drugs. The most
common combinations were with cocaine and THC.
Medicinal drugs
Finnish drivers tested signiﬁcantly more frequently positive for
benzodiazepines than Italian, Lithuanian, and Dutch drivers
(p< .05) (Table 3). However, after correction for age and gender,
the signiﬁcance disappeared. The highest prevalence in male
drivers was found in Finland (12.8%), and in female drivers in
Belgium (8.9%). In Italy, signiﬁcantly more female drivers tested
positive for benzodiazepines than male drivers. In three out of
ﬁve countries where benzodiazepines were found, a higher prev-
alence was recorded among drivers older than 35 years. The vast
majority of the benzodiazepine-positive drivers tested also posi-
tive for another psychoactive substance.
As for the benzodiazepines, Finnish drivers tested signiﬁcantly
more positive for Z-drugs than Italian, Lithuanian, and Dutch
drivers (p< .05). However, the signiﬁcance disappeared after
correction for age and gender. Only one positive driver was
recorded in the Netherlands and none in Italy and Lithuania.
Z-drugs were signiﬁcantly more common among drivers older
than 35 years in BE and DK (p< .05). Approximately half of the
positive drivers were also positive for another substance.
The highest prevalence of medicinal opioids was recorded in
Lithuania (Table 3) (p< .05). This was almost double compared
to the other countries. This difference remained signiﬁcant, even
after correction for age and gender. Medicinal opioids were
observed in both genders and in all age groups. Approximately
half the cases were found in combination with other substances,
mostly alcohol.
Combinations
The highest prevalence of alcohol-drug combinations was found
in Belgium (13.2%). Belgium also had the highest prevalence of
male (16.1%) and female drivers (6.4%) testing positive for an
Table 3. (Continued)
BELGIUM DENMARK FINLAND ITALY LITHUANIA THE NETHERLANDS
% (N) % (N) %(N) % (N) % (N) % (N)
Female 4.9 (5)* 1.4 (4) 0.0 (0) 0.0 (0)
<35y 0.0 (0) 0.4 (2) 3.6 (1) 0.0 (0)
≥35y 2.6 (4)*d 2.2 (8)* 4.0 (1) 1.2 (1)
Medicinal opioids 3.3 (11) 4.2 (35) 4.0 (2) 3.7 (25) 7.8 (30) 0.5 (1)
CI 1.8–5.7 3.0–5.8 1.2–13.0 2.5–5.4 5.5–10.9 0.1–2.9
Alone 1.8 2.5 2.0 1.8 5.7 0.5
Male 3.4 (8) 3.5 (19) 2.6 (1) 3.5 (18) 10.1 (24) 0.7 (1)
Female 3.1 (3) 5.5 (16) 9.1 (1) 4.5 (7) 3.7 (5)** 0.0 (0)
<35y 4.0 (7) 1.9 (9) 0.0 (0) 4.2 (14) 6.5 (13)e 0.0 (0)
≥35y 1.9(3)b 6.9 (25)b 8.0 (2) 3.2 (11) 8.6 (14) 1.2 (1)
Alcohol–Drug
combination
13.2 (43) 5.4 (45) 10.6 (5) 4.6 (31) 2.3 (9) 4.3 (8)
CI 10.0–17.2 4.1–7.1 4.9–21.6 3.3–6.5 1.2–4.3 2.2–8.2
Male 16.1 (37) 7.6 (41)* 13.5 (5) 5.2 (27) 2.5 (6) 4.7 (7)
Female 6.4 (6) 1.4 (4) 0.0 (0) 2.6 (4) 2.2 (3) 2.7 (1)
<35y 14.5 (24) 6.6 (31) 15.4 (4) 5.4 (18) 1.5 (3) 7.5 (8)*
≥35y 9.6 (14)h 3.9 (14) 4.8 (1) 3.8 (13) 3.1 (5)b 0.0 (0)
Drug–Drug
combination
2.5 (8) 3.5 (29) 4.3 (2) 2.5 (17) 0.8 (3) 0.5 (1)
CI 1.3–4.7 2.5–5.0 1.3–13.4 1.6–4.0 0.3–2.3 0.1–2.9
Male 3.0 (7) 3.7 (20) 5.4 (2) 3.3 (17)* 1.3 (3) 0.7 (1)
Female 1.1 (1) 3.1 (9) 0.0 (0) 0.0 (0) 0.0 (0) 0.0
<35y 3.6 (6) 3.4 (16) 3.8 (1) 3.6 (12) 0.5 (1) 0.9 (1)
≥35y 1.4 (2) 3.6 (13) 4.8 (1) 1.5 (5) 0.6 (1)b 0.0
aFor the calculation of the prevalence of positive drivers substance groups were mutually exclusive. A subject could only be part of one group only,
independently of the number of substances taken, either the driver tested positive or not.
* Signiﬁcant difference in distribution of positive drivers by age or gender (p< .05) within a country.
** For one driver positive for medicinal opioids gender was unknown.
CI = conﬁdence interval.
bFor 1 positive driver age was unknown.
cFor 4 positive drivers age was unknown.
dFor 2 positive drivers age was unknown.
eFor 3 positive drivers age was unknown.
fFor 6 positive drivers age was unknown.
gFor 9 positive drivers age was unknown.
hFor 5 positive drivers age was unknown.
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alcohol-drug combination. In the majority of the countries, this
combination was more prevailing among drivers younger than
35 years. Drug combinations were mostly observed among male
drivers. Female drivers positive for a drug combination were only
observed in Belgium (1.1%) and Denmark (3.1%). Prevailing alco-
hol-drug combinations were alcohol and benzodiazepines (1.1%)
and alcohol and cannabis (0.8%). The most common drug-drug
combinations were cannabis and cocaine (0.2%) and cannabis
and medicinal opioids (0.2%).
Discussion
Summary of the results
This study conﬁrms that psychoactive substances are frequently
detected in blood of seriously injured drivers.[9,15,17,27,33] Belgium
and Finland had the highest prevalence of alcohol and drugs
(roughly 40% of positive drivers in Finland and 50% in Belgium)
compared to about 30% in the other countries. For Finland this
can be explained by the fact that psychoactive substances aremore
frequently used by the general population than in other European
countries (e.g. Denmark, the Netherlands, and Germany).[34] The
sample size in Finland was low, with large error margins. The prev-
alence found in Belgium was similar to previous studies.[23,35]
Alcohol
Alcohol (BAC ≥ 0.1 g/L) was the most common ﬁnding, with few
(approximately 10%) BACs <.05 g/L. Other studies found similar
results.[16,27] Among the alcohol-positive drivers, 66% had a
BAC ≥ 1.3 g/L. In a recent report, the estimated prevalence of alco-
hol (BAC ≥ 1.3 g/L) among the general driving population in
Europe, was 0.39%.[36] This result was based on the outcome of
13 roadside surveys in different European countries. If one could
keep this small group of drivers with very high BAC-levels (≥1.3 g/
L) off the roads, the number of (alcohol-positive) crashes would
signiﬁcantly drop.
A much higher prevalence of alcohol was found among
Belgian drivers (BAC> 0.1 g/L: 42.5%; BAC> 0.5 g/L: 38.2%)
compared to the other ﬁve countries. This percentage was also
higher than in the two previous studies conducted in Belgium
(BAC> 0.5 g/L: 35.5%[23] and 34%,[35,37] respectively.[23,35]
Belgium also had one of the highest alcohol prevalence in the
recent DRUID roadside survey.[36]
No signiﬁcant differences in the distribution of alcohol concen-
trations were found between the countries. This is notable since
in the DRUID roadside survey, signiﬁcant differences in the distribu-
tion of alcohol concentrations were recorded.[36] Approximately
60% of the Italian and Lithuanian alcohol-positive injured drivers
had a BAC ≥0.5 g/l, while in the other countries this was only
20–40%. The high prevalence of high BACs in injured drivers (about
66% of all drivers had a BAC≥ 1.3 g/L) suggests a high crash risk
when driving with such a high BAC. Recent risk estimation calcula-
tions have conﬁrmed that driving with a high BAC (≥1.3 g/L) causes
a very high risk of getting injured in a car crash.[38]
Illicit drugs
Cannabis was the most common illicit drug, except in Finland. In
Europe, it has been estimated that the prevalence of cannabis
among injured drivers varies from 3.3–10.0%.[25] Two reviews of
studies from European and non-European countries reported
prevalence rates of 5–16.9% among non-fatally injured drivers,[39]
and 4–14% among injured or fatally injured drivers.[40] In the
present study, the prevalence of cannabis ranged from 0.5
(LT and NL) to 7.6% (BE), which is rather low compared to previ-
ous studies. Cannabis prevalence was especially high in Belgium,
mainly in young (<35 years) male drivers, which conﬁrms the
ﬁndings of other studies.[21,41–43] A notable ﬁnding is the low
prevalence found in the Netherlands where only one injured
driver (0.5%) tested positive for cannabis. Roadside surveys
performed between January 2007 and July 2009 recorded a prev-
alence of 1.67% among Dutch drivers compared to 0.35% among
Belgian drivers.[36] Based on these ﬁgures, a higher prevalence of
cannabis was expected among injured drivers the Netherlands.
For other illicit drugs, major differences were found among the
countries. Some variations exist between the injured drivers
sample of the six countries (e.g. signiﬁcantly more male drivers
in Italy), which could partially explain the variations that exist in
the presence of illicit drugs between the countries. Ampheta-
mines were more common in northern Europe, while cocaine
was more prevalent in southern Europe. Danish and Swedish
studies report similar prevalence data[21,44] for amphetamine.
The prevalence of cocaine found in Italy (2.7%) is similar to the
one recorded in another Italian study (3%).[45] A recent study
performed in Spain found an even higher percentage of cocaine-
positive drivers (male drivers = 7.2%; female drivers = 3.8%).[46] In
general, the prevalence of cocaine found in our study ismuch lower
than in studies from the United States, Denmark, and France (range
between 3.6–18.7%).[3,21,27,43,47,48] Finally, illicit opiates were only
found in Belgium, Denmark, Italy, and Lithuania. In the DRUID
roadside surveys, the prevalence of illicit opiates among the
general driving population was< 0.1% in all countries except
Italy (0.3%).[36]
Medicinal drugs
Weobservedmajor differences between the countries. Benzodiaze-
pines were the most prevailing medicinal drugs in Belgium,
Denmark, and Finland, while medicinal opioids were more preva-
lent in the other three countries. The highest prevalence of medic-
inal drugs was found in Finland and Denmark, which corresponds
to previous data for the Nordic countries.[17,49] However the
conﬁdence intervals in Finland were wide due to the low sample
size (benzodiazepines: 4.6–21.1%; Z-drugs: 1.2–12.7%). Belgian
Figure 1. Distribution of positive alcohol ﬁndings by BAC-group (in g/L)
and by country.
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drivers tested rather frequently positive for benzodiazepines and
Z-drugs (7.3%). This could be expected since Belgium has still one
of the highest benzodiazepine consumptions in Europe.[50–52]
Secondly, in the DRUID roadside survey, a higher prevalence of
benzodiazepines was observed in the Belgian general driving
population (2.02%) compared to other countries (NL:0.44%,
DK:0.51%, FIN:1.08%; LT:1.44%; IT:1.72%).[36] Some other studies
found a prevalence of benzodiazepines ranging between
1.2–9.6%.[3,8,21,41,42,47,48] Benzodiazepines and Z-drugs were
recorded in both genders, and more frequently in the older age
groups (>35 years). However, supratherapeutic blood concentra-
tions were recorded in only 30 cases (7.3%). This suggests that
medicinal drug use was of a therapeutic nature rather than from
abuse. Nevertheless, the fact that medicinal drugs were usually
detected at sub-therapeutic or therapeutic levels does not exclude
a potential driving impairment caused by these drugs, especially as
case–control studies revealed that the use of therapeutic doses of,
for example, benzodiazepines elevates the risk of motor vehicle
accidents.[38,53–55] One should also note that medicinal drugs
were very often found in combination with alcohol or other, mostly
illicit, drugs.
Combinations
Most substances were found in combination with alcohol or other
drugs, from approximately 50% up to 100% of the positive drivers.
The high prevalence of drug combinations among injured drivers
conﬁrms that the risk increases exponentially when substances
are combined.[1,38,42,53,56,57] In the DRUID roadside survey, the
weighted average percentage was only 0.37% and 0.39%, respec-
tively, for combinations with alcohol and other drug classes.[36]
The synergistic effect of the combination of alcohol and other
drugs, resulting in high risk, makes it especially important to iden-
tify this group and to remove it from the road. Moreover, our study
provides evidence that focusing only on alcohol in trafﬁc safety
initiatives will miss the other drugs that are found in a signiﬁcant
proportion of drivers involved in crashes.
From our data, it is apparent that a large percentage of drivers
involved in trafﬁc crashes in Europe have alcohol or drugs in their
blood. These ﬁndings would further motivate effective preven-
tive actions directed against drink and drug-driving. In several
countries (e.g. the Netherlands, France, Sweden, and Finland),
drink-drivers can only regain the right to drive by having an
alcohol interlock device (alcolock) installed in their car.
Studies showed that alcolocks are useful in both commercial
and non-commercial contexts and result in a decrease of
recidivism.[58,59] With regard to medicinal drugs, putting a (legal)
responsibility on both the patients and the physician might be
a preventive strategy.[60] Healthcare professionals should be
encouraged to inform patients about the potential increase
in crash risk when taking certain medicinal drugs such as
benzodiazepines. Unfortunately, a recent study showed that
patient knowledge regarding driving under the inﬂuence of
medicines was rather low. The authors concluded that by
increasing healthcare-provided awareness about medicines
and driving, patient knowledge would also increase.[61]
For all six countries, these data clearly indicate that for the two
most common drugs, alcohol and cannabis, young male drivers
(under 35 years) are the most at-risk driver group. On the other
hand medicinal drugs (benzodiazepines, medicinal opioids and
z-drugs) were more frequently observed in female and older
drivers (over 35 years).
The high prevalence rates of psychoactive substances among
crash-involved drivers might provide a justiﬁcation for routine
testing for the most common impairing substances in the emer-
gency department. Furthermore, identifying the presence of
alcohol and/or drugs, which is often associated with cross-
tolerance to a number of sedative and analgesic medications,
may also assist in pain management.[46,62] Finally, a detection in
the emergency department helps to identify problematic users
of alcohol and drugs and to refer them to an appropriate treat-
ment at an early stage.[63]
Strengths and limitations of the study
As far as we know, this is the ﬁrst study on seriously injured
drivers performed simultaneously in various countries using a
common study design, which allows comparison of results
between the countries involved.
There are some limitations, however, with regard to the study
design and data collection. The hospitals involved in the present
study did not always cover the whole of the participating
countries. Therefore, some questions can be raised concerning
representativeness. Secondly, when applying all inclusion criteria,
the sample size for some countries (e.g. FI and NL) became rather
small. It is recommended that in future research drivers with an
MAIS 1 injury score are also included. There is no clear evidence
that the use of psychoactive substances is related to more severe
accidents.[64,65] Furthermore, the inclusion percentage of the six
studies is not known. Therefore it is impossible to estimate
whether selective inclusion introduced a bias.
Although hospital staff was asked to record any drug adminis-
tered to the driver before blood sampling, there is a possibility
that in some cases this was not done. This may have led to an
overestimation of the prevalence of benzodiazepines and medic-
inal opioids. Finally, the maximum delay between the crash and
blood sampling was 3 h. The drug concentrations can decrease
between the time of the crash and the blood sampling. There-
fore, in most cases the measured concentration was lower than
at the time of the crash.
Conclusions
This study conﬁrms the high prevalence of psychoactive
substances in seriously injured drivers, but we observed major
differences between the studied countries. Alcohol (≥ 0.1 g/L)
was the most common ﬁnding. Notable are the many drivers hav-
ing a BAC ≥ 1.3 g/L. Cannabis was the most prevailing illicit drug,
with benzodiazepines and medicinal opioids the most common
medicinal drugs. Illicit drugs were more prevalent among male
drivers younger than 35 years, while medicinal drugs were found
more often among female drivers older than 35. The majority of
psychoactive substances were found in combination with other
ones, mostly alcohol. The high prevalence of high BACs and
combinations (compared to the roadside survey) suggest that
those drivers are most at risk and that preventive actions should
target them preferentially.
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